theMednetRegister

Endocrinology

Cardiology   

Questions discussed in this category

Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
1 Answer available
For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting? 
4 Answers available
In ischemic stroke patients with low LDL levels (<30-50 mg/dl), would you consider lowering LDL levels to lower values without concern for any side effects?
How would you adjust statin therapy in these patients?
4 Answers available
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods? 
1 Answer available
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
Ferrell et al., PMID 38448791
6 Answers available
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
Butt et al., PMID 39818225
1 Answer available
Besides treadmill, what other exercises may be considered for post-exercise ABIs, and are their diagnostic parameters identical to standard post-exercise ABIs?
1 Answer available
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?
1 Answer available
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
Chen & Zhong, AHA/ASA Journals 2024
2 Answers available
Will TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome, also lower triglycerides due to other genetic causes of hypertriglyceridemia?
2 Answers available
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
1 Answer available
Are recurrent UTIs a contraindication to SGLT2i use?
4 Answers available
Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?
4 Answers available
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Prattichizzo et al., PMID 39468384
1 Answer available
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
1 Answer available
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
Butler et al., PMID 38587237
1 Answer available
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
1 Answer available
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
1 Answer available
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
1 Answer available
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
1 Answer available
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
At what doses do you start? and how do you titrate therapy?
1 Answer available
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
ESPRIT Trial
1 Answer available
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
Cholesterol Treatment Trialists' (CTT) Collaboration
2 Answers available
Is ABI (Ankle Brachial index) lower limb arterial doppler not recommended if patient already has arterial stents in the legs, and if so, what other imaging modality would you consider as first-line?
1 Answer available
When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?
3 Answers available
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
1 Answer available
Is there enough evidence now to use injectable semaglutide as a foundational therapy for symptomatic heart failure with preserved ejection fraction in the setting of overweight or obesity?
1 Answer available
Do you recommend continuing SGLT2 inhibitors in patients with diabetic kidney disease and congestive heart failure who have been taking the medication for several years and later develop end stage kidney disease?
3 Answers available
Should a toe-brachial index be obtained in lieu of resting ABI as an initial screen for PAD in high-risk patients such as those with longstanding diabetes or advanced age with stiffened vessels?
1 Answer available
Do you change management in patients that are taking bisphosphonates and develop atrial fibrillation?
1 Answer available


Papers discussed in this category

The New England journal of medicine, 2015 Sep 17
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine, 2020 Sep 24
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine, 2023 Aug 25
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Curr Rheumatol Rep, 2020 Aug 26
Lipid-lowering Therapies in Myositis.
The New England journal of medicine, 2024 Apr 06
Empagliflozin after Acute Myocardial Infarction.
The American journal of cardiology, 2004-02-01
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Nature medicine, 2024 Feb 19
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.
Journal of clinical lipidology, 2024 Mar 29
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.
Journal of the American College of Cardiology, 1986-12
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
The New England journal of medicine, 2011-12-15
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Current opinion in lipidology, 2007 Aug
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.
The American journal of cardiology, 2005 Jun 01
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Trials, 2018 Mar 05
Improved adherence adjustment in the Coronary Drug Project.
The New England journal of medicine, 2014 Jul 17
Effects of extended-release niacin with laropiprant in high-risk patients.
JAMA, 1975 Jan 27
Clofibrate and niacin in coronary heart disease.
Stroke, 2007-12
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
The New England journal of medicine, 2006 Aug 10
High-dose atorvastatin after stroke or transient ischemic attack.
European heart journal, 2020 Jan 01
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Journal of the American Heart Association, 2023 Sep 08
Statin Treatment in Patients With Stroke With Low-Density Lipoprotein Cholesterol Levels Below 70 mg/dL.
The New England journal of medicine, 2011-12-01
Effect of two intensive statin regimens on progression of coronary disease.
Lancet (London, England), 2024 Jun 27
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
Circulation, 2019-06-18
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
The New England journal of medicine, 2016 Sep 15
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine, 2023 Nov 11
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
N Engl J Med, 2015 Nov 09
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Diabetes care, 2025 Jan 01
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.
The New England journal of medicine, 2024 Apr 07
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
The New England journal of medicine, 2022 Apr 21
Calorie Restriction with or without Time-Restricted Eating in Weight Loss.
The lancet. Healthy longevity, 2024 Apr 05
Effects of 3 months of 10-h per-day time-restricted eating and 3 months of follow-up on bodyweight and cardiometabolic health in Danish individuals at high risk of type 2 diabetes: the RESET single-centre, parallel, superiority, open-label, randomised controlled trial.
Diabetes & metabolic syndrome, 2024 Feb 05
Does early time-restricted eating reduce body weight and preserve fat-free mass in adults? A systematic review and meta-analysis of randomized controlled trials.
Journal of clinical lipidology, 2022 Sep 11
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.
The lancet. Diabetes & endocrinology, 2025 Feb 13
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.

Related Topics in Endocrinology

Copyright © 2025 theMednet
All Rights Reserved.